Expanded access study of iodine-131 anti-B1 antibody [iodine-131 tositumomab] for relapsed/refractory low-grade and transformed low-grade non-Hodgkin's lymphoma
Phase of Trial: Phase III
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Iodine-131 tositumomab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Expanded access; Therapeutic Use
- 22 Nov 2010 Planned End Date (1 Jan 2015) added as reported by ClinicalTrials.gov record.
- 10 Sep 2005 New trial record.